A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations

{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2022, 4, 2]], 'date-time': '2022-04-02T05:54:28Z', 'timestamp': 1648878868157}, 'posted': {'date-parts': [[2021, 3, 8]]}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'reference-count': 37, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2021, 3, 8]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Many drugs have been suggested to be used for ' 'Covid-19. A suitable and efficient choice of drug would make the course of Covid-19 easier. ' 'we have investigated the efficacy of different treatment regimen in reducing hospitalization ' 'period (HP) and mortality of 324 confirmed Covid-19 patients. Received drugs included single ' 'therapy or combinations of Methylprednisolone, Remdesivir, Favipiravir, Interferon β1a, and ' 'Dexamethasone. HP and mortality were compared between different treatment groups to evaluate ' 'efficacy of each drug. HP and mortality were also calculated for patients in each treatment ' 'group based on their underlying diseases and age. we suggest that using IFN-β1a, RDV and ' 'corticosteroids might not have a significant effect on the HP or mortality of the Covid-19 ' 'patients as it was thought before.</jats:p>', 'DOI': '10.1101/2021.03.05.21251351', 'type': 'posted-content', 'created': {'date-parts': [[2021, 3, 8]], 'date-time': '2021-03-08T17:45:19Z', 'timestamp': 1615225519000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, ' 'Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations', 'prefix': '10.1101', 'author': [ {'given': 'Sahand Tehrani', 'family': 'Fateh', 'sequence': 'first', 'affiliation': []}, {'given': 'Sepand Tehrani', 'family': 'Fateh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Esmaeil', 'family': 'Salehi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nima', 'family': 'Rezai', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nazanin', 'family': 'Haririan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Abdollah', 'family': 'Asgari', 'sequence': 'additional', 'affiliation': []}, {'given': 'Amir', 'family': 'Salehi-Najafabadi', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2021031010100751000_2021.03.05.21251351v1.1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(20)30120-1'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.2', 'doi-asserted-by': 'crossref', 'first-page': '988', 'DOI': '10.1016/j.cmi.2020.05.019', 'article-title': 'Review of trials currently testing treatment and prevention of COVID-19', 'volume': '26', 'year': '2020', 'journal-title': 'Clin. Microbiol. Infect'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.3', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0232391'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.4', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.26302'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.5', 'doi-asserted-by': 'crossref', 'first-page': '200', 'DOI': '10.1016/j.micinf.2020.05.012', 'article-title': 'Arbidol/IFN-α2b therapy for patients with coronavirus disease 2019: a ' 'retrospective multicenter cohort study', 'volume': '22', 'year': '2020', 'journal-title': 'Microbes Infect'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.6', 'doi-asserted-by': 'publisher', 'DOI': '10.1101/2020.03.17.20037432'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.7', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.eng.2020.03.007'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.8', 'doi-asserted-by': 'crossref', 'unstructured': 'Fadel Raef, A. M. Early Short Course Corticosteroids in Hospitalized ' 'Patients with COVID-19. (2020).', 'DOI': '10.1101/2020.05.04.20074609'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.9', 'doi-asserted-by': 'publisher', 'DOI': '10.1101/2020.05.11.20097709'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.10', 'unstructured': 'R Core Team. R: A Language and Environment for Statistical Computing. ' '(2020).'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.11', 'unstructured': 'RStudio Team. RStudio: Integrated Development Environment for R. ' '(2020).'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.12', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acs.jmedchem.6b01594'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.13', 'unstructured': 'USFoodandDrugAdministration. Coronavirus (COVID-19) update: FDA issues ' 'Emergency Use Authorization for potential COVID-19 treatment. ' 'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment ' '(2020).'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.14', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/nejmoa2007764'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.15', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)31022-9'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.16', 'doi-asserted-by': 'crossref', 'first-page': '1048', 'DOI': '10.1001/jama.2020.16349', 'article-title': 'Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in ' 'Patients with Moderate COVID-19: A Randomized Clinical Trial', 'volume': '324', 'year': '2020', 'journal-title': 'JAMA - J. Am. Med. Assoc'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.17', 'first-page': '2019', 'article-title': 'Remdesivir for 5 or 10 Days in Patients with Severe Covid-19', 'volume': '2019', 'year': '2020', 'journal-title': 'N. Engl. J. Med'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.18', 'doi-asserted-by': 'publisher', 'DOI': '10.2183/pjab.93.027'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.19', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ejps.2020.105631'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.20', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/resp.13196'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.21', 'first-page': '1', 'volume': '6', 'year': '2018', 'journal-title': 'Interferon-β 1a inhibits SARS-CoV-2 in vitro when administered after ' 'virus infection Nicola'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.22', 'doi-asserted-by': 'crossref', 'unstructured': 'Davoudi-Monfared, E. et al. A randomized clinical trial of the efficacy ' 'and safety of interferon β-1a in treatment of severe COVID-19. ' 'Antimicrob. Agents Chemother. 64, (2020).', 'DOI': '10.1128/AAC.01061-20'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.23', 'first-page': '1', 'article-title': 'Interferon beta-1a as a Candidate for COVID-19 Treatment;An Open-Label ' 'Single-Arm Clinical Trial', 'volume': '4', 'year': '2020', 'journal-title': 'Adv. J. Emerg. Med'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.24', 'doi-asserted-by': 'crossref', 'first-page': '106688', 'DOI': '10.1016/j.intimp.2020.106688', 'article-title': 'Subcutaneous administration of interferon beta-1a for COVID-19: A ' 'non-controlled prospective trial', 'volume': '85', 'year': '2020', 'journal-title': 'Int. Immunopharmacol'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.25', 'doi-asserted-by': 'crossref', 'unstructured': 'Bani-Sadr, F. et al. Corticosteroid therapy for patients with COVID-19 ' 'pneumonia: a before-after study. Int. J. Antimicrob. Agents 56, (2020).', 'DOI': '10.1016/j.ijantimicag.2020.106077'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.26', 'doi-asserted-by': 'crossref', 'first-page': '1149', 'DOI': '10.1080/17476348.2020.1804365', 'article-title': 'Mortality in COVID-19 patients with acute respiratory distress syndrome ' 'and corticosteroids use: a systematic review and meta-analysis', 'volume': '14', 'year': '2020', 'journal-title': 'Expert Rev. Respir. Med'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.27', 'doi-asserted-by': 'crossref', 'first-page': '2392', 'DOI': '10.3390/jcm9082392', 'article-title': 'Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A ' 'Systematic Review and Meta-Analysis', 'volume': '9', 'year': '2020', 'journal-title': 'J. Clin. Med'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.28', 'doi-asserted-by': 'crossref', 'first-page': '1330', 'DOI': '10.1001/jama.2020.17023', 'article-title': 'Association between Administration of Systemic Corticosteroids and ' 'Mortality among Critically Ill Patients with COVID-19: A Meta-analysis', 'volume': '324', 'year': '2020', 'journal-title': 'JAMA - J. Am. Med. Assoc'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.29', 'doi-asserted-by': 'crossref', 'first-page': '1317', 'DOI': '10.1001/jama.2020.17022', 'article-title': 'Effect of Hydrocortisone on Mortality and Organ Support in Patients ' 'with Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain ' 'Randomized Clinical Trial', 'volume': '324', 'year': '2020', 'journal-title': 'JAMA - J. Am. Med. Assoc'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.30', 'doi-asserted-by': 'crossref', 'unstructured': 'Hu, Z. et al. Clinical Use of Short-Course and Low-Dose Corticosteroids ' 'in Patients With Non-severe COVID-19 During Pneumonia Progression. ' 'Front. Public Heal. 8, (2020).', 'DOI': '10.3389/fpubh.2020.00355'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.31', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41422-020-0282-0'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.32', 'doi-asserted-by': 'crossref', 'first-page': '416', 'DOI': '10.5694/mja2.50577', 'article-title': 'Corticosteroid treatment of patients with coronavirus disease 2019 ' '(COVID-19)', 'volume': '212', 'year': '2020', 'journal-title': 'Med. J. Aust'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.33', 'doi-asserted-by': 'crossref', 'unstructured': 'Gangopadhyay, K. K. et al. Title Page Title : The role of ' 'corticosteroids in the management of critically ill patients with ' 'coronavirus disease 2019 (COVID-19): A meta-analysis Author details : ' 'Abstract Objective : Data Sources : Data extraction : Data synthesis: ' '(2020).', 'DOI': '10.1101/2020.04.17.20069773'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.34', 'doi-asserted-by': 'crossref', 'unstructured': 'Tlayjeh, H. et al. Efficacy of Corticosteroids in COVID-19 Patients: A ' 'Systematic Review and Meta-Analysis. medRxiv (2020).', 'DOI': '10.1101/2020.08.13.20174201'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.35', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40121-020-00332-3'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.36', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0232391'}, { 'key': '2021031010100751000_2021.03.05.21251351v1.37', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-020-59121-0'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2021.03.05.21251351', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 3, 10]], 'date-time': '2021-03-10T18:10:41Z', 'timestamp': 1615399841000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2021.03.05.21251351'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 3, 8]]}, 'references-count': 37, 'URL': 'http://dx.doi.org/10.1101/2021.03.05.21251351', 'relation': {}, 'subject': [], 'published': {'date-parts': [[2021, 3, 8]]}, 'subtype': 'preprint'}